Stay updated with breaking news from Complete Remission. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Feb. 22, 2023 /PRNewswire/ -- Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children.
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical...
Investegate announcements from F. Hoffmann-La Roche Ltd, FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab
Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse